Drugs / CAL056
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04686383 | Dec 2020 → Jun 2022 | refractory malignant neoplasm | Calgent Biotechnology Co., Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAL056 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04686383 ↗ |
| Route | Oral | “Patients will receive oral dose of 20 mg CAL056 mesylate once daily under fasting condition in the morning for 28 days during each cycle.” NCT04686383 ↗ |